عرض بسيط للتسجيلة

المؤلفChemaitelly, Hiam
المؤلفAyoub, Houssein H.
المؤلفAlMukdad, Sawsan
المؤلفFaust, Jeremy S.
المؤلفTang, Patrick
المؤلفCoyle, Peter
المؤلفYassine, Hadi M.
المؤلفAl Thani, Asmaa A.
المؤلفAl-Khatib, Hebah A.
المؤلفHasan, Mohammad R.
المؤلفAl-Kanaani, Zaina
المؤلفAl-Kuwari, Einas
المؤلفJeremijenko, Andrew
المؤلفKaleeckal, Anvar H.
المؤلفLatif, Ali N.
المؤلفShaik, Riyazuddin M.
المؤلفAbdul-Rahim, Hanan F.
المؤلفNasrallah, Gheyath K.
المؤلفAl-Kuwari, Mohamed G.
المؤلفButt, Adeel A.
المؤلفAl-Romaihi, Hamad E.
المؤلفAl-Thani, Mohamed H.
المؤلفAl-Khal, Abdullatif
المؤلفBertollini, Roberto
المؤلفAbu-Raddad, Laith J.
تاريخ الإتاحة2023-09-26T06:01:42Z
تاريخ النشر2023-09-05
اسم المنشورJournal of travel medicine
المعرّفhttp://dx.doi.org/10.1093/jtm/taad106
الاقتباسHiam Chemaitelly, Houssein H Ayoub, Sawsan AlMukdad, Jeremy S Faust, Patrick Tang, Peter Coyle, Hadi M Yassine, Asmaa A Al Thani, Hebah A Al-Khatib, Mohammad R Hasan, Zaina Al-Kanaani, Einas Al-Kuwari, Andrew Jeremijenko, Anvar H Kaleeckal, Ali N Latif, Riyazuddin M Shaik, Hanan F Abdul-Rahim, Gheyath K Nasrallah, Mohamed G Al-Kuwari, Adeel A Butt, Hamad E Al-Romaihi, Mohamed H Al-Thani, Abdullatif Al-Khal, Roberto Bertollini, Laith J Abu-Raddad, Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB* infections, Journal of Travel Medicine, Volume 30, Issue 5, July 2023, taad106, https://doi.org/10.1093/jtm/taad106
الرقم المعياري الدولي للكتاب1195-1982
معرّف المصادر الموحدhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85169846797&origin=inward
معرّف المصادر الموحدhttp://hdl.handle.net/10576/47962
الملخصIn October of 2022, Qatar introduced COVID-19 bivalent vaccination for persons ≥ 12 years using the 50-μg mRNA-1273.214 vaccine combining SARS-CoV-2 ancestral and omicron BA.1 strains.1 We estimated this vaccine’s effectiveness against SARS-CoV-2 infection. Using Qatar’s national SARS-CoV-2 databases, we conducted a matched, retrospective, cohort study to compare infection incidence in the national cohort of persons who received the vaccine (bivalent cohort) to that in the national cohort of Qatar residents whose last vaccination was ≥6 months before follow-up start (no-recent-vaccination cohort; Supplementary Appendix 1). The 6-month cut-off was chosen because of negligible effectiveness of first-generation vaccines against omicron infection ≥ 6 months after vaccination.2 Incidence of infection was defined as the first SARS-CoV-2 PCR-positive or rapid-antigen-positive test after the start of follow-up, regardless of symptoms. Cohorts were balanced on observed confounders through exact matching. Follow-up started 7 days after the person in the bivalent cohort received their vaccine dose. Associations were estimated using Cox proportional-hazards models adjusted for the matching factors and testing rate.
اللغةen
الموضوعasymptomatic infection
Hybrid immunity
natural infection
Qatar
variant-containing COVID-19 vaccines
waning vaccine effectiveness
العنوانBivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB* infections
النوعArticle
رقم العدد5
رقم المجلد30
ESSN1708-8305
dc.accessType Open Access


الملفات في هذه التسجيلة

Thumbnail

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة